PDF(Pubmed)
Abstract：
UNASSIGNED: Secondary pyeloplasty for recurrent ureteropelvic junction obstructions may be a safe and feasible surgical option for patients. This study aimed to demonstrate outcomes of utilizing a non-transecting buccal mucosa graft ureteroplasty for management of recurrent ureteropelvic junction obstruction after prior failed pyeloplasty.
UNASSIGNED: We performed a retrospective review of our Collaborative of Reconstructive Robotic Ureteral Surgery database for all consecutive patients who underwent buccal mucosa graft ureteroplasty between April 2012 and June 2022 for management of recurrent ureteropelvic junction obstructions after prior failed pyeloplasty. The primary outcome included surgical success which was defined as the absence of flank pain and no obstruction on imaging.
UNASSIGNED: Overall, ten patients were included in our analysis. The median stricture length was 2.5 (interquartile range [IQR] 1.8-4.0) cm. The median operative time was 230.5 (IQR 199.5-287.0) min and median estimated blood loss was 50.0 (IQR 28.8-102.5) mL. At a median follow-up of 10.3 (IQR 6.2-14.8) months, 80% of patients were surgically successful and there were no major (Clavien-Dindo Grade>2) complications.
UNASSIGNED: Buccal mucosa graft ureteroplasty is a valuable non-transecting surgical option for patients with recurrent ureteropelvic junction obstructions who failed prior pyeloplasty and has comparable outcomes to the literature regarding standard transecting techniques.
UNASSIGNED: We performed a retrospective review of our Collaborative of Reconstructive Robotic Ureteral Surgery database for all consecutive patients who underwent buccal mucosa graft ureteroplasty between April 2012 and June 2022 for management of recurrent ureteropelvic junction obstructions after prior failed pyeloplasty. The primary outcome included surgical success which was defined as the absence of flank pain and no obstruction on imaging.
UNASSIGNED: Overall, ten patients were included in our analysis. The median stricture length was 2.5 (interquartile range [IQR] 1.8-4.0) cm. The median operative time was 230.5 (IQR 199.5-287.0) min and median estimated blood loss was 50.0 (IQR 28.8-102.5) mL. At a median follow-up of 10.3 (IQR 6.2-14.8) months, 80% of patients were surgically successful and there were no major (Clavien-Dindo Grade>2) complications.
UNASSIGNED: Buccal mucosa graft ureteroplasty is a valuable non-transecting surgical option for patients with recurrent ureteropelvic junction obstructions who failed prior pyeloplasty and has comparable outcomes to the literature regarding standard transecting techniques.
摘要：
■对于复发性肾盂输尿管连接部阻塞，二次肾盂成形术可能是患者安全可行的手术选择。这项研究旨在证明在肾盂成形术失败后，利用非横断颊粘膜移植物输尿管成形术治疗复发性肾盂输尿管连接部梗阻的结果。
我们对2012年4月至2022年6月期间接受颊粘膜移植输尿管成形术治疗肾盂肾盂成形术后复发性输尿管连接部阻塞的所有连续患者进行了回顾性审查。主要结果包括手术成功，其定义为无侧腹疼痛且影像学无阻塞。
■总的来说，我们的分析包括10例患者.中位狭窄长度为2.5（四分位距[IQR]1.8-4.0）cm。中位手术时间为230.5（IQR199.5-287.0）min，中位估计失血量为50.0（IQR28.8-102.5）mL。在中位随访10.3(IQR6.2-14.8)个月时，80%的患者手术成功并且没有重大(Clavien-Dindo分级>2)并发症。
■颊粘膜移植输尿管成形术是一种有价值的非横断性手术选择，适用于肾盂输尿管连接部复发性阻塞患者，这些患者先前肾盂成形术失败，其结果与标准横断技术的文献相当。
我们对2012年4月至2022年6月期间接受颊粘膜移植输尿管成形术治疗肾盂肾盂成形术后复发性输尿管连接部阻塞的所有连续患者进行了回顾性审查。主要结果包括手术成功，其定义为无侧腹疼痛且影像学无阻塞。
■总的来说，我们的分析包括10例患者.中位狭窄长度为2.5（四分位距[IQR]1.8-4.0）cm。中位手术时间为230.5（IQR199.5-287.0）min，中位估计失血量为50.0（IQR28.8-102.5）mL。在中位随访10.3(IQR6.2-14.8)个月时，80%的患者手术成功并且没有重大(Clavien-Dindo分级>2)并发症。
■颊粘膜移植输尿管成形术是一种有价值的非横断性手术选择，适用于肾盂输尿管连接部复发性阻塞患者，这些患者先前肾盂成形术失败，其结果与标准横断技术的文献相当。
